JP2011519414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519414A5 JP2011519414A5 JP2011501777A JP2011501777A JP2011519414A5 JP 2011519414 A5 JP2011519414 A5 JP 2011519414A5 JP 2011501777 A JP2011501777 A JP 2011501777A JP 2011501777 A JP2011501777 A JP 2011501777A JP 2011519414 A5 JP2011519414 A5 JP 2011519414A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- virus
- dlvr
- clec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 241000700605 Viruses Species 0.000 claims 6
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/079,576 US7943134B2 (en) | 2005-08-31 | 2008-03-27 | Compositions and methods for identifying response targets and treating flavivirus infection responses |
| US12/079,576 | 2008-03-27 | ||
| PCT/US2008/065166 WO2009120225A1 (en) | 2008-03-27 | 2008-05-29 | Compositions and methods for identifying response targets and treating flavivirus infection responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011519414A JP2011519414A (ja) | 2011-07-07 |
| JP2011519414A5 true JP2011519414A5 (enExample) | 2011-11-10 |
Family
ID=39722300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011501777A Ceased JP2011519414A (ja) | 2008-03-27 | 2008-05-29 | 応答標的の同定及びフラビウイルス感染反応の治療に用いる組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7943134B2 (enExample) |
| EP (1) | EP2257806A4 (enExample) |
| JP (1) | JP2011519414A (enExample) |
| CN (1) | CN102084250B (enExample) |
| AU (1) | AU2008353452A1 (enExample) |
| BR (1) | BRPI0822472A2 (enExample) |
| GB (1) | GB2458715A (enExample) |
| TW (1) | TWI403586B (enExample) |
| WO (1) | WO2009120225A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8354127B2 (en) * | 2008-02-12 | 2013-01-15 | Academia Sinica | Structure and bioactivity of the polysaccharides and oligomers in medicinal plant Dendrobium huoshanense |
| EP2906596B1 (en) | 2012-10-12 | 2023-12-27 | Arizona Board of Regents on behalf of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
| WO2014183469A1 (zh) * | 2013-05-16 | 2014-11-20 | 清华大学 | 一种用于登革热预防和/或治疗的疫苗 |
| JP6764348B2 (ja) | 2014-02-11 | 2020-09-30 | ビステラ， インコーポレイテッド | デングウイルスに対する抗体分子およびその使用 |
| WO2017165736A1 (en) | 2016-03-25 | 2017-09-28 | Visterra, Inc. | Formulation of antibody molecules to dengue virus |
| CN110475873A (zh) * | 2017-03-16 | 2019-11-19 | 中央研究院 | 诊断病毒感染的方法 |
| US20220331349A1 (en) * | 2019-01-08 | 2022-10-20 | University Of Georgia Research Foundation, Inc. | Targeted nanoparticles and their uses related to fungal infections |
| CN113122628B (zh) * | 2019-12-30 | 2023-08-11 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | Clec5a基因作为标志物在子宫内膜癌中诊断及治疗的应用 |
| CN111650308B (zh) * | 2020-07-13 | 2022-10-14 | 贵州中医药大学 | 一种金钗石斛花的hplc指纹图谱构建方法 |
| US11197910B1 (en) * | 2020-08-19 | 2021-12-14 | Vitruviae LLC | Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases |
| CN113713105A (zh) * | 2021-09-13 | 2021-11-30 | 中国人民解放军军事科学院军事医学研究院 | 用于抑制clec5a的物质在制备治疗和/或预防乙型病毒性肝炎的药物中的应用 |
| CN115029789A (zh) * | 2022-05-31 | 2022-09-09 | 南通大学 | DC-SIGN的shRNA库的构建及其在原发性肝癌中的应用 |
| CN115804362A (zh) * | 2023-02-08 | 2023-03-17 | 中国医学科学院医学生物学研究所 | 一种IFN-α/βR-/-小鼠抗体依赖性增强感染的注射液及其制备方法 |
| CN118515783B (zh) * | 2024-06-06 | 2024-11-08 | 威瑞生物科技(昆明)有限责任公司 | 新冠病毒N蛋白和编码S1抗原mRNA分子结合的仿生病毒结构疫苗及其制备方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) * | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) * | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) * | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) * | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4946787A (en) * | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5506337A (en) * | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US4774085A (en) * | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5010175A (en) * | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| CA2044593C (en) | 1989-11-03 | 2004-04-20 | Kenneth L. Brigham | Method of in vivo delivery of functioning foreign genes |
| US5270163A (en) * | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5288514A (en) * | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| US5519134A (en) * | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5593853A (en) * | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
| US5539083A (en) * | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| US5525735A (en) * | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
| US5549974A (en) * | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
| US5977322A (en) | 1995-06-14 | 1999-11-02 | The Regents Of The University Of California | High affinity human antibodies to tumor antigens |
| US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5569588A (en) * | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| US6416973B1 (en) * | 1997-08-01 | 2002-07-09 | Schering Corporation | Nucleic acids encoding mammalian cell membrane protein MDL-1 |
| EP1386004A4 (en) * | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
| GB0112649D0 (en) | 2001-05-24 | 2001-07-18 | Isis Innovation | Macrophage receptor |
| JP2005504741A (ja) | 2001-07-17 | 2005-02-17 | ユニバーシティー オブ ヴァージニア パテント ファウンデーション | 改良されたヘテロポリマー複合体およびそれらの使用法 |
| MY151032A (en) * | 2002-07-19 | 2014-03-31 | Abbott Lab S A | Treatment of tnf? related disorders |
| WO2004041299A1 (en) * | 2002-11-05 | 2004-05-21 | Institut Pasteur | Dc-sign blockers and their use for preventing or treating viral infections. |
| WO2006052975A2 (en) * | 2004-11-08 | 2006-05-18 | Schering Corporation | Tumor association of mdl-1 and methods |
| US20070072247A1 (en) * | 2005-08-31 | 2007-03-29 | Academia Sinica | Methods and reagents for the analysis and purification of polysaccharides |
| AR059193A1 (es) * | 2006-01-31 | 2008-03-12 | Bayer Schering Pharma Ag | Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias |
| JP2010526066A (ja) * | 2007-04-23 | 2010-07-29 | シェーリング コーポレイション | 抗ｍｄｌ−１抗体 |
-
2008
- 2008-03-27 US US12/079,576 patent/US7943134B2/en active Active
- 2008-05-29 WO PCT/US2008/065166 patent/WO2009120225A1/en not_active Ceased
- 2008-05-29 AU AU2008353452A patent/AU2008353452A1/en not_active Abandoned
- 2008-05-29 JP JP2011501777A patent/JP2011519414A/ja not_active Ceased
- 2008-05-29 EP EP08873539A patent/EP2257806A4/en not_active Withdrawn
- 2008-05-29 CN CN200880129343.0A patent/CN102084250B/zh not_active Expired - Fee Related
- 2008-05-29 BR BRPI0822472-2A patent/BRPI0822472A2/pt not_active IP Right Cessation
- 2008-07-15 GB GB0812915A patent/GB2458715A/en not_active Withdrawn
-
2009
- 2009-03-27 TW TW098110058A patent/TWI403586B/zh not_active IP Right Cessation
-
2011
- 2011-05-12 US US13/106,046 patent/US8460669B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011519414A5 (enExample) | ||
| WO2009039248A3 (en) | Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection | |
| WO2010107739A3 (en) | Methods and compositions of treating a flaviviridae family viral infection | |
| WO2009060429A3 (en) | Compositions for conferring tolerance to viral disease in social insects, and the use thereof | |
| EA200870304A1 (ru) | Псевдоинфекционный флавивирус и его применение | |
| EA200701850A1 (ru) | Соединения трициклических нуклеозидов (варианты), фармацевтическая композиция на их основе и способ лечения или профилактики вирусных инфекций у млекопитающих | |
| CL2011002453A1 (es) | Compuestos derivados de diazol u oxazol-pirrol o pirrolciclopropil condensados sustituidos, inhibidores de la función de la proteína ns5a codificada por el virus de la hepatitis c (vhc); composición farmacéutica; y su uso para el tratamiento de una infección por vhc. | |
| CL2007003250A1 (es) | Compuestos derivados de isoquinolina, inhibidores del virus de hepatitis c; composicion farmaceutica; y uso para el tratamiento de una infeccion por vhc. | |
| WO2006075993A3 (en) | Nucleoside derivatives for treating hepatitis c virus infection | |
| CY1111423T1 (el) | Αναστολεις ns5b hcv | |
| CL2009000305A1 (es) | Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv). | |
| EA201201356A1 (ru) | Композиция для лечения респираторных синцитиальных вирусов | |
| WO2007140200A3 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
| WO2007140254A3 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
| CL2004001161A1 (es) | Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c. | |
| DE602005027580D1 (de) | Inhibitoren der rna-abhängigen rna-polymerase des hepatitis-c-virus und zusammensetzungen und behandlungen, bei denen diese verwendet werden | |
| TW200745035A (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
| BRPI0811447A2 (pt) | Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c. | |
| TW200745120A (en) | Indolobenzazepine HCV NS5B inhibitors | |
| BRPI0415883A (pt) | compostos e composições de nucleosìdeo para o tratamento de infecções virais | |
| JP2008526876A5 (enExample) | ||
| WO2010030538A3 (en) | Compounds for the treatment of hepatitis c | |
| DE602006015861D1 (de) | Antivirale verbindungen | |
| WO2006096459A3 (en) | Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof | |
| EA200800932A1 (ru) | Модифицированные 4`-нуклеозиды в качестве противовирусных агентов |